Keytruda

Keytruda hits primary endpoint in confirmatory lymphoma trial

The trial compared Keytruda to Seattle Genetic’s antibody-drug conjugate Adcetris – a standard treatment for relapsed and refractory lymphoma. ... CHL is, in comparison to Keytruda’s other indications, not quite as important.

Putting commercial intelligence at the heart of strategy

Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting

IMV preps pivotal trials for ovarian cancer T cell therapy

The therapy is being tested alongside Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in two phase 2 studies, including an investigator-led trial in patients with advanced-stage diffuse large

BMS scores first oesophageal cancer nod for Opdivo in Japan

The approval in oesophageal cancer is particularly important for BMS as it continues to fight for its place in the PD-1/L1 inhibitor class, while Merck &Co’s Keytruda (pembrolizumab) ... That includes Keytruda, Roche’s Tecentriq (atezolizumab),

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... The TACTI-002 trial is testing eftilagimod alpha

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]